Evidence Report: Risk of Ineffective or Toxic Medication During Long-Duration Exploration SpaceflightThe scope of this report is limited to evaluating drug stability with respect to spaceflight. The effects of spaceflight on drug pharmacokinetics (PK) or drug pharmacodynamics (PD) are not addressed in this report: these topics will be reviewed in future reports. This is the first report of the available evidence pertaining to the chemical and physical stability of drugs in the context of drug impurity, drug repackaging, and exposure to ionizing space radiation. Previous studies are discussed within this report and, where possible, the data are interpreted and contextualized with regards to drug stability.
Document ID
20230018496
Acquisition Source
Johnson Space Center
Document Type
Other - Technical Report
Authors
John F. Reichard (University of Cincinnati Cincinnati, Ohio, United States)
Kris R. Lehnhardt (Baylor College of Medicine Houston, United States)
Benjamin D. Easter (University of Colorado Denver Denver, United States)
Jay Lemery (University of Colorado Denver Denver, United States)
S. Robin Elgart (Johnson Space Center Houston, United States)
Virginia E. Wotring (Baylor College of Medicine Houston, United States)